Request for Free Sample

Gene Editing Market Size & Trends

The Gene Editing Market size was valued at USD 6.09 billion in 2024 and is expected to reach USD 15.46 billion by 2032, growing at a CAGR of 12.21% over the forecast period of 2025-2032.

The global gene editing market is growing robustly, fueled by developments in CRISPR and other genome engineering technologies. The market is rapidly expanding with rising R&D investments, high demand for personalized medicine, and rising activity in clinical trials. These regulatory approvals of CRISPR-based therapies such as Casgevy represent a new step into the clinical stage. Pharmaceutical partnerships, academic collaborations,  and use in drug discovery, genetic engineering, and rare disease treatment are all contributing to further pushes in the market.

March 2025-Doctors at the Children's Hospital of Philadelphia (CHOP) and Penn Medicine successfully treated an infant—K.J. Muldoon—born with a life-threatening integration of severe carbamoyl phosphate synthetase 1 (CPS1) deficiency,  one of the most severe forms of urea cycle disorder and a rare metabolic disorder that's usually fatal in the first weeks of life aka using a person center gene editing therapy based on CRISPR.

The U.S. gene editing market size was valued at USD 1.95 billion in 2024 and is expected to reach USD 4.82 billion by 2032, growing at a CAGR of 11.88% over the forecast period of 2025-2032. North America dominated the global gene editing market, with the U.S. being a major national market due to its highly developed healthcare infrastructure, immense presence of biotechnological companies, and a significant amount of investment in R&D. This is also where most of the active clinical trials and regulatory initiatives are taking place providing further credence to their leading position in gene editing.

In June 2025, U.S.-pharmaceutical giant Eli Lilly & Co. laid out its intention to take over gene-editing biotech company Verve Therapeutics Inc. in a USD 1.3 billion deal. The takeover is a strategic step by Lilly to enhance its position in experimental medicine and fuel long-term growth.

Gene Editing Market Dynamics:

Drivers

  • Market Growth is Driven by the Advancements of Gene-Editing Technologies

Innovative tools such as CRISPR-Cas9, TALEN, ZFN, and next-generation platforms such as base editing and prime editing have driven the gene editing market substantially forward. Of these, CRISPR-Cas9 is a new, easy, cheap, and precise method for cutting and changing DNA at precisely defined sites in the DNA molecule. This has led to newer improvements on the original CRISPR method, and not only specific but also off-target effects have been reduced, making it more substantial for therapeutic effects. Advancements in this technology have widened the scope of gene editing for applications such as disease treatment, plant breeding, and synthetic biology, consequently fuelling the demand and accelerating the gene editing market growth.

Over the years, prime editing technologies (PE2, PE3, and PEmax) have shown up to 10-fold higher precision & efficiency compared to CRISPR, with off rates lower than 0.1% in organoids and mouse embryos.

  • Increasing Clinical Trials and Regulatory Approvals are Propelling the Market Growth

The CRISPR-based therapy clinical trials and regulatory approvals were a major turning point for the gene editing market. A notable example is the CRISPR-based therapy Casgevy (exagamglogene autotemcel) by CRISPR Therapeutics and Vertex Pharmaceuticals, approved in 2023 to treat sickle cell disease and transfusion-dependent beta-thalassemia. These milestones have confirmed the safety and effectiveness of genetic modification for human treatments and also increased the confidence of investors, regulators, and healthcare providers in gene editing. The continued growth of the gene editing market should help to grow the global market as more gene editing candidates progress through clinical pipelines.

In January 2025, the UK NHS approved the CRISPR-based therapy cassegvy (exagamglogene autotemcel) for unhappy with sickle cell disease and beta-thalassemia, following FDA approval (late 2023)

CRISPR Therapeutics AG, the personalized in vivo CRISPR treatment effective against a rare CPS1 deficiency developed in six months. This personalized in vivo CRISPR paves the way towards precision gene therapies of rare diseases for the first time.  

Restraint

  • Ethical and Regulatory Challenges are Restraining the Market Growth

The ethical and regulatory complexity of gene editing use, especially for humans,  is a major restraint for the gene editing market. Certain kinds of contemporary genome technologies, especially CRISPR, can be used to change the DNA of humans, specifically germline cells (which can pass changes along at least one generation). This leads to profound ethical dilemmas regarding what science should be able to do, with fears about so-called designer babies, the potential for unintended consequences, and social inequality in access to such high-end treatments.

This has led many nations and regulatory bodies to implement stringent regulations or prohibitions on some categories of gene editing, most notably, those of reproductive or non-therapeutic nature. Uncertain regulations can also push the clinical trials, limit research funds, and prevent companies from pursuing bold but morally ambiguous new projects. The result is a fragmented and hesitant regulatory environment that makes it hard to transition gene editing therapies from the lab to the clinic.

Gene Editing Market Segmentation Analysis:

By Product and Services

In 2024, the reagents & consumables segment dominated the gene editing market share with 71.56%, owing to its essential requirement for conducting gene editing experiments in research as well as clinical settings. These products include, but aren't limited to, the enzymes, nucleases, guide RNAs, plasmids, and buffers required for CRISPR, TALEN, and ZFN-based protocols. The increasing global academic research, therapeutic development, and preclinical study continued to expand, requiring an ongoing need for high-quality, reproducible, and purpose-built reagents. Moreover, the segment accounted for the highest revenue share in 2024 due to the frequent requirement for restocking in laboratories.

With increasing complexity in gene editing workflows and the need for precision, automation, and data analytics to analyze the associated data, the Software & Systems segment is projected to grow at the fastest CAGR throughout the forecast period. Sophisticated software tools for CRISPR guide design, off-target prediction, gene annotation, and workflow optimization are becoming increasingly vital for executing efficient genome editing. Moreover,  integrated systems and platforms that automate editing processes are being adopted in biotech corporations and research institutes. The transition from low-throughput to high-throughput applications with AI-assisted genome analysis is driving the adoption of software and systems used in gene editing.

By Technology

Due to its high efficiency, ease of use, and cost-effectiveness as compared to earlier gene editing technologies, the clustered regularly interspaced short palindromic repeats (CRISPR) segment dominated the 2024 gene editing market with a 73.5% market share. The advent of CRISPR-Cas9 has changed the paradigm of genome editing by enabling targeted changes within genomes of living organisms and has led to rapid widespread use in research and therapeutic applications. CRISPR has maintained its leadership position in the gene editing technology landscape, bolstered by broad-based applications in drug discovery, functional genomics, and disease modeling, and with growing clinical trial activity for CRISPR-null and CRISPR-based therapies.

September 2024: To significantly enhance guide RNA design accuracy, scientists create a deep-learning model named DeepFM-Crispr for predicting on-target and off-target effects of CRISPR-Cas13d.

TALEN (transcription activator-like effector nucleases) segment is estimated to be the fastest growing segment over the years because of the increasing application in precision therapy, as they are more precise and have less off-target activity. TALENs are most suitable for gene editing in complicated scenarios with mating, such as CAR-T cell therapy and regenerative medicine. With CRISPR under investigation in the clinic, and its off-target mutations and delivery barriers being more critically evaluated, TALEN is receiving more attention again for its safety and versatility. This segment is anticipated to witness high growth owing to the surge in investment being made into the TALEN-based technologies and their growing implementation in personalized medicine.

By Application

The cell line engineering segment dominated the gene editing market with a 58.2% market share in 2024 because of its importance in drug discovery, preclinical studies, and the production of biologics. With the proliferation of gene editing tools such as CRISPR-Cas9, tailored cell lines that mimic human disease, drug response, and therapeutic protein production are being generated. Engineered cell lines are an important tool used by pharmaceutical and biotechnology companies, as well as academic research institutes, to facilitate efficient target validation and toxicity testing.

The genetic engineering segment is anticipated to witness the fastest growth, due to rising applications of genetic engineering in therapeutic development, agriculture, and synthetic biology during the forecast period. Gene therapy innovations (e.g., in vivo editing of disease-causing mutations) are revolutionizing the treatment of inherited and rare disorders. Also, the convention of using plant and animal genomes for better traits is further stimulating adoption. Gene editing is expected to go up due to more advanced therapy in the clinical pipeline and clearer regulatory pathways for any kind of direct genetic modification in humans and other organisms, and this will drive the growth of the genetic engineering segment over the forecast period.

By End-user

The gene editing market was dominated by the Pharmaceutical and biotechnology companies segment with an 89.4% market share in 2024, which led in both the development of therapeutics and the commercialization innovation. These firms are also delving heavily into gene editing technologies, specifically CRISPR, to produce targeted treatments, gene therapies, and personalized medicine solutions. This has the pharma-biotech sector leveraging R&D investments, partnerships, and clinical trial activity largely focused on editing genetic disorders to lead it downstream to market revenue. Finally, their stronghold was cemented by a demand for engineered cell lines, high-throughput screening (HTS), and biologics manufacturing.

Due to fuelling funding, availability of open-source gene editing tools, and a global need for high-end biomedical research, the academic and research institutes segment is expected to be the fastest-growing segment over the forecast period. Basic research enhancing the precision, safety, or delivery of gene editing is being done at universities and government-funded labs, where the lion's share of innovation occurs. Academic places are opening up in addition to CRISPR, TALEN, as well as other editing platforms interest in functional genomics, unusual illness modeling, and agricultural biotechnology proceeds to grow.

Gene Editing Market Regional Insights:

The gene editing market is dominated by North America with a 43.1% market share in 2024, due to the strong biotechnology and pharmaceutical industry, strong research infrastructure, and significant government and private sector funding. It is also a region where top gene editing companies have positioned themselves, including CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, all of which are now progressing clinical trials and commercialization of CRISPR-based therapies. With early adoption of new sophisticated technologies and facilities in the healthcare and academia, supported by strong regulatory frameworks, especially in the U.S., it increases the region’s market access and innovation lead.

For instance, according to NCBI, Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a central regulator of cholesterol metabolism. In the U.S., two fully human monoclonal antibodies, alirocumab and evolocumab, have been approved by the FDA to inhibit or decrease PCSK9 activity. In more recent developments, both the FDA and the European Union have authorized inclisiran, a small interfering RNA (siRNA), which is intended to block intracellular PCSK9 production.

Europe exhibits significant growth in the gene editing market, driven largely by government funding for both public and private research programs throughout the EU and the UK. Academics work with industry hand in hand within Europe, and the strength of collaboration between academia and industry in the region is a huge asset, particularly but not limited to such countries as Germany, France, and the Nordics, to enable preclinical research and to move early clinical research forward. Development of CRISPR, base-editing, and related technologies is being accelerated by support from the European Commission — € 1 billion+ Horizon Europe funding — and emerging biotech clusters. Moreover, the increasing focus on precision medicine and regulatory harmonization in Europe (through EMA guidance) is also facilitating the commercialization of gene editing therapies and strengthening the market position of this region.

Asia Pacific is the fastest-growing region in the gene editing market with a 12.82% CAGR over the forecast period, with an increase in government funding for genomics research, and well-established biotech hubs, along with growing demand for personalized medicine, are some key factors. Recent investments in genome-editing capacities are being made, for example, in China, Japan, South Korea, and India, along with increasing clinical trial and academic parallels in these regions. Also, the gene editing application is expected to witness high growth with a huge number of genetic disorders in the region, coupled with a high population provides high market potential for gene editing in research as well as therapeutic applications.

Moderate growth is anticipated in the Latin America and MEA regions due to gradual developments in the research infrastructure and rising interest in genomics among academia. The country is making some advances in regulatory harmonization and increasing access to its biotech ecosystems, but still has low to modest availability of new capital and high-end technology, such as the U.S. in Latin America. International research institutions are working collaboratively to fill the gap and gradually increase regional capacity.

The growth of the market in MEA is attributed to rising government expenditure to develop biotechnology and life science sectors in countries like the UAE, Saudi Arabia, and South Africa. The demand for genomic research, healthcare innovation, and agricultural biotechnology is on the rise, creating new possible avenues for gene editing applications. However, limitations such as funding and trained professionals are still posing challenges to the market; yet, strategic partnerships and investments are paving the way for the subsequent development of the market in the region.

Gene Editing Market Key Players: 

CRISPR Therapeutics AG, Editas Medicine, Inc., Intellia Therapeutics, Inc., Precision BioSciences, Inc., Beam Therapeutics Inc., Verve Therapeutics, Inc., Sangamo Therapeutics, Inc., Thermo Fisher Scientific Inc., Horizon Discovery (a PerkinElmer Company), GenScript Biotech Corporation, and other players.

Recent Developments in the Gene Editing Market:

  • May 2025 – Intellia Therapeutics, Inc., a clinical-stage gene editing leader, reported positive two-year follow-up results from its Phase 1 trial of nexiguran ziclumeran (nex-z) in the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).

  • May 2025 – Editas Medicine, a leader in gene editing technologies, shared in vivo proof-of-concept data to support the development of a potentially first-in-class treatment for an undisclosed liver target. The results were presented at a poster session at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in New Orleans. This breakthrough reflects Editas' ongoing innovation in CRISPR-based therapeutic development.
  • March 2024 – CRISPR Therapeutics AG, a world-leading gene-editing company, achieved a milestone moment in March 2024 with the approval of Casgevy (exagamglogene autotemcel)—the first CRISPR gene-edited therapy.

    Gene Editing Market Report Scope:
    Report Attributes Details
    Market Size in 2024 USD 6.09 Billion 
    Market Size by 2032 USD 15.46 Billion 
    CAGR CAGR of 12.21% From 2025 to 2032
    Base Year 2024
    Forecast Period 2025-2032
    Historical Data 2021-2023
    Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
    Key Segments • By Product & Services (Reagents & Consumables, Software & Systems, Services)
    • By Technology (Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Transcription Activator-Like Effector Nuclease (TALEN), Zinc Finger Nuclease (ZFN), Antisense, Other Technologies)
    • By Application (Cell Line Engineering, Genetic Engineering, Drug Discovery & Development, Other Applications)
    • By End-user (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes)
    Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
    Company Profiles CRISPR Therapeutics AG, Editas Medicine, Inc., Intellia Therapeutics, Inc., Precision BioSciences, Inc., Beam Therapeutics Inc., Caribou Biosciences, Inc., Sangamo Therapeutics, Inc., Thermo Fisher Scientific Inc., Horizon Discovery (a PerkinElmer Company), GenScript Biotech Corporation, and other players.